Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01QNR
|
|||
| Drug Name |
PIM447
|
|||
| Synonyms |
VRQXRVAKPDCRCI-ZNMIVQPWSA-N; PIM-447; 1210608-43-7; PIM447 (LGH447); N-{4-[(1r,3s,5s)-3-Amino-5-Methylcyclohexyl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide; N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide; UNII-9TG5O4V25H; SCHEMBL3215332; GTPL9790; 9TG5O4V25H; CHEMBL3651966; PIM 447 [WHO-DD]; BDBM106870; ZINC116907270; AKOS032945086; CS-5929; compound 8 [PMID: 26505898]; HY-19322; J3.552.648J; US8592455, 70; 5H7; 2-Pyr
Click to Show/Hide
|
|||
| Indication | Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 1 | [1] | |
| Company |
Novartis Oncology East Hanover, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H23F3N4O
|
|||
| Canonical SMILES |
CC1CC(CC(C1)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
|
|||
| InChI |
1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
|
|||
| InChIKey |
VRQXRVAKPDCRCI-ZNMIVQPWSA-N
|
|||
| CAS Number |
CAS 1210608-43-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase pim (PIM) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.